Repopulation of cancer cells during therapy: an important cause of treatment failure - Kim, J. J.; Tannock, I. F. (Nat Rev Cancer, 2005)

Radiation oncology: a century of achievements - Bernier, J.; Hall, E. J.; Giaccia, A. (Nat Rev Cancer, 2004)

How can we overcome tumor hypoxia in radiation therapy? - Harada, H. (J Radiat Res, 2011)

Radiation-induced genomic instability and its implications for radiation carcinogenesis - Huang, L.; Snyder, A. R.; Morgan, W. F. (Oncogene, 2003)

Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glio-blastoma - Wild-Bode, C.; Weller, M.; Rimner, A.; Dichgans, J.; Wick, W. (Cancer Res, 2001)

Current status and new developments in ion therapy - Karger, C. P.; Jäkel, O. (Strahlenther Onkol, 2007)

Biomarkers for personalized oncology: recent advances and future challenges - Kalia, M. (Metabolism, 2015)

Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines—does scheduling matter? - Harrabi, S.; Combs, S. E.; Brons, S.; Haberer, T.; Debus, J.; Weber, K. J. (Int J Radiat Biol, 2013)

Combining radiotherapy and cancer immunotherapy: a paradigm shift - Formenti, S. C.; Demaria, S. (J Natl Cancer Inst, 2013)

Cancer genes and the pathways they control - Vogelstein, B.; Kinzler, K. W. (Nat Med, 2004)

Neoplastic development, - Foulds, L. (Academic Press, 1969)

Carcinogenesis as a multistage process—experimental evidence - Weinstein, I. B. (IARC Press, 1982)

(untitled) - Nordling, C. O. (BR J Cancer, 1953)

Only three driver gene mutations are required for the development of lung and colorectal cancers - Tomasetti, C.; Marchionni, L.; Nowak, M. A.; Parmigiani, G.; Vogelstein, B. (PNAS, 2015)

Hallmarks of cancer: the next generation - Hanahan, D.; Weinberg, R. A. (Cell, 2011)

Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies - Li, Y. i. n. g. h. u. i.; Tergaonkar, V. i. n. a. y. (Cancer Res, 2014)

Molecular imaging of cancer with positron emission tomography - Gambhir, S. S. (Nat Rev Cancer, 2002)

Links between metabolism and cancer - Dang, C. V. (Genes Dev, 2012)

Anti-angiogenic therapy for cancer: an update - Al-Husein, B.; Abdalla, M.; Trepte, M.; DeRemer, D. L.; Somanath, P. R. (Pharmacotherapy, 2012)

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability - Colotta, F.; Allavena, P.; Sica, A.; Garlanda, C.; Mantovani, A. (Carcinogenesis, 2009)

Inflammation and lung carcinogenesis: applying findings in prevention and treatment - Peebles, K. A.; Lee, J. M.; Mao, J. T. (Expert Rev Anti-cancer Ther, 2007)

Replicative senescence: implications for in vivo aging and tumor suppression - Smith, J. R.; Pereira-Smith, O. M. (Science, 1996)

Cellular senescence: when bad things happen to good cells - Campisi, J.; di Fagagna, F. A. (Nat Rev Mol Cell Biol, 2007)

Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors - Campisi, J. (Cell, 2005)

The essence of senescence - Kuilman, T.; Michaloglou, C.; Mooi, W. J.; Peeper, D. S. (Genes Dev, 2010)

CDK inhibitors: positive and negative regulators of G1-phase progression - Sherr, C. J.; Roberts, J. M. (Genes Dev, 1999)

Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all - Gil, J.; Peters, G. (Nat Rev Mol Cell Biol, 2006)

Human melanocyte senescence and melanoma susceptibility genes - Bennett, D. C. (Oncogene, 2003)

The p16INK4a/CDKN2A tumor suppressor and its relatives - Ruas, M.; Peters, G. (Biochim Biophys Acta, 1998)

Expression of CDK7/CAK in normal and tumor cells of diverse histogenesis, cell-cycle position and differentiation - Bartkova, J.; Zemanova, M.; Bartek, J. (Int J Cancer, 1996)

Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets - Walker, G. J.; Flores, J. F.; Glendening, J. M.; Lin, A. H.; Markl, I. D.; Fountain, J. W. (Genes Chromosomes Cancer, 1998)

Senescence-associated oxidative DNA damage promotes the generation of neoplastic cells - Gosselin, K.; Martien, S.; Pourtier, A. (Cancer Res, 2009)

Cancer, aging and cellular senescence - Campisi, J. (In Vivo, 2000)

Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics - Kerr, J. F. R.; Wyllie, A. H.; Currie, A. R. (Br J Cancer, 1972)

How death shapes life during development - Baehrecke, E. H. (Nat Rev Mol Cell Biol, 2002)

Programmed cell death in animal development and disease - Fuchs, Y.; Steller, H. (Cell, 2011)

Apoptosis in cancer: from pathogenesis to treatment - Wong, R. S. Y. (J Exp Clin Cancer Res, 2011)

p53: structure, function and therapeutic applications - Bai, L.; Zhu, W. G. (J Cancer Mol, 2006)

p53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation - Avery-Kiejda, K. A.; Bowden, N. A.; Croft, A. J. (BMC Cancer, 2011)

Cell cycle checkpoints, genetic instability and cancer - Weinert, T.; Lydall, D. (Semin Cancer Biol, 1993)

Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice - Liu, G.; Parant, J. M.; Lang, G. (Nat Genet, 2004)

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP - Lu, M.; Breyssens, H.; Salter, V. (Cancer Cell, 2013)

Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53 - Mercer, W. E.; Shields, M. T.; Amin, M.; Sauve, G. J.; Appella, E.; Romano, J. W.; Ullrich, S. J. (Proc Natl Acad Sci USA, 1990)

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 - Scheffner, M.; Werness, B. A.; Huibregtse, J. M.; Levine, A. J.; Howley, P. M. (Cell, 1990)

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a - Serrano, M.; Lin, A. W.; McCurrach, M. E.; Beach, D.; Lowe, S. W. (Cell, 1997)

Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line - Shaw, P.; Bovey, R.; Tardy, S.; Sahli, R.; Sordat, B.; Costa, J. (Proc Natl Acad Sci USA, 1992)

Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 - Yonish-Rouach, E.; Resnitzky, D.; Lotem, J.; Sachs, L.; Kimchi, A.; Oren, M. (Nature, 1991)

Genetic instability and Darwinian selection in tumours - Cahill, D. P.; Kinzler, K. W.; Vogelstein, B.; Lengauer, C. (Trends Cell Biol, 1999)

Structure and function of telomeres - Blackburn, E. H. (Nature, 1991)

Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins - Martínez, P.; Blasco, M. A. (Nat Rev Cancer, 2011)

The RNA component of human telomerase - Feng, J.; Funk, W. D.; Wang, S. S. (Science, 1995)

Telomerase catalytic subunit homologs from fission yeast and human - Nakamura, T. M.; Morin, G. B.; Chapman, K. B. (Science, 1997)

Telomere dynamics and telomerase activity in in vitro immortalised human cells - Bryan, T. M.; Reddel, R. R. (Eur J Cancer, 1997)

Telomerase activity in normal and malignant hematopoietic cells - Broccoli, D.; Young, J. W.; Lange, T. (Proc Natl Acad Sci USA, 1995)

Direct activation of TERT transcription by c-MYC - Wu, K. J.; Grandori, C.; Amacker, M. (Nat Genet, 1999)

A survey of telomerase activity in human cancer - Shay, J. W.; Bacchetti, S. (Eur J Cancer, 1997)

Telomere elongation in immortal human cells without detectable telomerase activity - Bryan, T. M.; Englezou, A.; Gupta, J.; Bacchetti, S. (EMBO J, 1995)

Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer - Hu, J.; Hwang, S. S.; Liesa, M. (Cell, 2012)

Poly (ADP-ribose) polymerase: molecular biological aspects - Murcia, G.; Menissier-de Murcia, J.; Schreiber, V. (BioEssays, 1991)

Involvement of poly (ADPribose) polymerase in base excision repair - Dantzer, F.; Schreiber, V.; Niedergang, C. (Biochimie, 1999)

Stereo specific PARP trapping by BMN 673 and comparison with olaparib and rucaparib - Murai, J.; Huang, S. Y.; Renaud, A. (Mol Cancer Ther, 2014)

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers - Fong, P. C.; Boss, D. S.; Yap, T. A. (N Engl J Med, 2009)

Mechanisms of resistance to therapies targeting BRCA-mutant cancers - Lord, C. J.; Ashworth, A. (Nat Med, 2013)

Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? - Bouwman, P.; Jonkers, J. (Clin Cancer Res, 2014)

APC restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer - Dow, L. E.; O’Rourke, K. P.; Simon, J.; Tschaharganeh, D. F.; Es, J. H.; Clevers, H.; Lowe, S. W. (Cell, 2015)

Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence - Larsson, L. G. (Semin Cancer Biol, 2011)

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis - Bartkova, J.; Horejsí, Z.; Koed, K. (Nature, 2005)

BRAFE600-associated senescence-like cell cycle arrest of human naevi - Michaloglou, C.; Vredeveld, L. C.; Soengas, M. S. (Nature, 2005)

Four faces of cellular senescence - Rodier, F.; Campisi, J. (J Cell Biol, 2011)

The hallmarks of cancer - Hanahan, D.; Weinberg, R. A. (Cell, 2000)

PRAK is essential for ras-induced senescence and tumor suppression - Sun, P.; Yoshizuka, N.; New, L.; Moser, B. A.; Li, Y.; Liao, R. (Cell, 2007)

Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence - Lin, H. K.; Chen, Z.; Wang, G. (Nature, 2010)

Roles and mechanisms of cellular senescence in regulation of tissue homeostasis - Ohtani, N.; Hara, E. (Cancer Sci, 2013)

Cancer immunotherapy comes of age - Topalian, S. L.; Weiner, G. J.; Pardoll, D. M. (J Clin Oncol, 2011)

Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines - Butt, A. Q.; Mills, K. H. G. (Oncogene, 2014)

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer - Topalian, S. L.; Hodi, F. S.; Brahmer, J. R. (N Engl J Med, 2012)

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab - Topalian, S. L.; Sznol, M.; Mcdermott, D. F. (J Clin Oncol, 2014)

Safety and tumor responses with lambrolizumab (anti- PD-1) in melanoma - Hamid, O.; Robert, C.; Daud, A. (N Engl J Med, 2013)

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma - Ansell, S. M.; Lesokhin, A. M.; Borrello, I. (N Engl J Med, 2015)

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers - Moreno, B. H.; Ribas, A. (Br J Cancer, 2015)

Therapeutic uses of anti-PD-1 and anti-PD-L1 Antibodies - Philips, G. K.; Atkins, M. (Int Immunol Jpn Soc Immunol, 2014)

Targeting the immune system in cancer - Chaudhuri, D.; Suriano, R.; Mittelman, A.; Tiwari, R. K. (Curr Pharm Biotechnol, 2009)

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy - Baxevanis, C. N.; Perez, S. A.; Papamichail, M. (Cancer Immunol Immunother, 2009)

New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies - Azijli, K.; Stelloo, E.; Peters, G. J.; Eertwegh, A. J. (Anti-cancer Res, 2014)

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice - Okazaki, T.; Okazaki, I. M.; Wang, J. (J Exp Med, 2011)

Opportunities and challenges in the development of experimental drug combinations for cancer - Humphrey, R.; Brockway-Lunardi, L.; Bonk, D. (J Natl Cancer Inst, 2011)